The Exchange has sought clarification from JHS Svendgaard Laboratories Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies -2. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
JHS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 3.9 pts less than its Personal Care peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NSE has asked JHS Svendgaard Laboratories to clarify certain issues with its financial results for the quarter ended 30-June-2025 under Regulation 33 of SEBI's Listing Obligations. The two specific points flagged are: (1) the financial results were not signed by an authorized signatory, and (2) the XBRL filing submitted to the exchange contained discrepancies. The company has not yet responded, and the exchange is awaiting its reply. No penalty or action has been announced at this stage.
This is a procedural compliance query and not a penalty or enforcement action. Investors should watch for the company's clarification, as unresolved discrepancies in financial filings can affect trading sentiment and signal weaknesses in internal controls.